Neurocrine

Biz Brief: Abbott Licenses Potential Gynecological Drug from Neurocrine

Abbott Laboratories and Neurocrine Biosciences have entered into a collaboration agreement to develop and commercialize a potential gynecological treatment, elagolix. Elagolix, a potential oral drug, which has completed Phase IIb trials, is being developed for the treatment of endometriosis and uterine fibroids.